ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1828

Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Abstract Number: 1144

Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic
Abstract Number: 0468

Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
Abstract Number: 0100

Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Abstract Number: PP03

Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Abstract Number: 1052

Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Abstract Number: 1878

Consensus Definitions for MRI Lesions in the Spine of Patients with Axial Spondyloarthritis: First Analysis from the Assessments in SpondyloArthritis International Society Classification Cohort
Abstract Number: 0741

Constitutive Inhibitor Kappa B (IκB) Kinase 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes
Abstract Number: 1084

Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients
Abstract Number: 2040

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Abstract Number: 0293

Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus
Abstract Number: 0707

Contribution of NOTUM and Glypicans to the Development of Osteoarthritis
Abstract Number: PP05

Coping Through Advocacy – My Story Living with Relapsing Polychondritis
Abstract Number: 1596

Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals
Abstract Number: 0413

Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].